Shares of AIM ImmunoTech Inc. (AIM) are rising over 30% in pre-market today, after the company announced that the U.S. FDA has authorized the first human trial assessing the safety and effectiveness of the company's lead asset, Ampligen (rintatolimod), in combination with interferon alfa-2b, in cancer patients with COVID-19, the disease caused by the SARS-CoV-2 coronavirus.
from RTT - Before the Bell https://ift.tt/2Z1L1vJ
via IFTTT
No comments:
Post a Comment